| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jiamei Lian, Bo Pan, Chao Den. Early antipsychotic exposure affects serotonin and dopamine receptor binding density differently in selected brain loci of male and female juvenile rats. Pharmacological reports : PR. vol 68. issue 5. 2017-03-20. PMID:27428765. |
this study aimed to investigate the effects of aripiprazole, olanzapine and risperidone on the binding of serotonin (5-ht) and dopamine receptors in juvenile rat brain regions that are involved in antipsychotic efficacy. |
2017-03-20 |
2023-08-13 |
rat |
| Matthew L Banks, Douglas A Smith, Bruce E Bloug. Methamphetamine-like discriminative stimulus effects of bupropion and its two hydroxy metabolites in male rhesus monkeys. Behavioural pharmacology. vol 27. issue 2-3 Spec Issue. 2016-12-13. PMID:26886209. |
in addition, varenicline, a partial agonist at the nach receptor, and risperidone, a dopamine antagonist, were tested as controls. |
2016-12-13 |
2023-08-13 |
monkey |
| Amit Taneja, An Vermeulen, Dymphy R H Huntjens, Meindert Danhof, Elizabeth C M De Lange, Johannes H Proos. Summary data of potency and parameter information from semi-mechanistic PKPD modeling of prolactin release following administration of the dopamine D2 receptor antagonists risperidone, paliperidone and remoxipride in rats. Data in brief. vol 8. 2016-09-12. PMID:27617278. |
summary data of potency and parameter information from semi-mechanistic pkpd modeling of prolactin release following administration of the dopamine d2 receptor antagonists risperidone, paliperidone and remoxipride in rats. |
2016-09-12 |
2023-08-13 |
rat |
| Amit Taneja, An Vermeulen, Dymphy R H Huntjens, Meindert Danhof, Elizabeth C M De Lange, Johannes H Proos. Summary data of potency and parameter information from semi-mechanistic PKPD modeling of prolactin release following administration of the dopamine D2 receptor antagonists risperidone, paliperidone and remoxipride in rats. Data in brief. vol 8. 2016-09-12. PMID:27617278. |
we provide the reader with relevant data related to our recently published paper, comparing two mathematical models to describe prolactin turnover in rats following one or two doses of the dopamine d2 receptor antagonists risperidone, paliperidone and remoxipride, "a comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine d2 receptor antagonists in rats" (taneja et al., 2016) [1]. |
2016-09-12 |
2023-08-13 |
rat |
| Serena Deiana, Akihito Watanabe, Yuki Yamasaki, Naoki Amada, Tetsuro Kikuchi, Colin Stott, Gernot Riede. MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol. Behavioural pharmacology. vol 26. issue 8 Spec No. 2016-08-22. PMID:26287433. |
collectively, the combined activity of aripiprazole on dopamine d2 and serotonin 5ht1a receptors appears to provide a significant advantage over risperidone and olanzapine with respect to the rescue of cognitive deficits reminiscent of schizophrenia. |
2016-08-22 |
2023-08-13 |
human |
| Matthew L Banks, Bruce E Bloug. Effects of Environmental Manipulations and Treatment with Bupropion and Risperidone on Choice between Methamphetamine and Food in Rhesus Monkeys. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 40. issue 9. 2016-04-26. PMID:25742872. |
the aims of this study were to develop a methamphetamine vs food choice procedure and determine treatment effects with two clinically relevant compounds: the monoamine uptake inhibitor bupropion and the dopamine antagonist risperidone. |
2016-04-26 |
2023-08-13 |
human |
| Yen-Feng Lee, Chia-Kuang Tsai, Chih-Sung Lian. High-Dose Risperidone Induced Latent Syndrome of Inappropriate Antidiuretic Hormone Secretion With Seizure Presentation. Clinical neuropharmacology. vol 38. issue 4. 2016-04-11. PMID:26166241. |
high-dose risperidone treatment is the most probable cause, and the mechanisms may be related to risperidone's high affinity for the 5-hydroxytryptamine 2a and dopamine 2 receptors. |
2016-04-11 |
2023-08-13 |
Not clear |
| Niraj Narendra Ravani, Pramod H Katk. Iloperidone-induced ejaculatory dysfunction: A case series. Indian journal of psychiatry. vol 58. issue 1. 2016-03-17. PMID:26985111. |
iloperidone, a new dopamine type 2 and serotonin type 2a antagonist similar to risperidone, provides better efficacy with lesser extra-pyramidal side effects. |
2016-03-17 |
2023-08-13 |
Not clear |
| Alan I Green, Mary F Brunette, Ree Dawson, Peter Buckley, Amy E Wallace, Hisham Hafez, Marvin Herz, Meera Narasimhan, Douglas L Noordsy, Christopher O'Keefe, Roger W Sommi, Richard M Steinbook, Marjorie Week. Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. The Journal of clinical psychiatry. vol 76. issue 10. 2016-03-14. PMID:26302441. |
we have proposed that risperidone's relatively potent dopamine d2 receptor blockade may partly underlie its lack of effect on alcohol use. |
2016-03-14 |
2023-08-13 |
Not clear |
| T F Meert, F Awouter. Central 5-HT2 antagonists: A preclinical evaluation of a therapeutic potential. Acta neuropsychiatrica. vol 2. issue 4. 2016-03-09. PMID:26952556. |
risperidone has, as opposed to classical neuroleptics such as haloperidol, less risks of inducing a dopamine d2 overblockade. |
2016-03-09 |
2023-08-13 |
Not clear |
| Hiroyoshi Takeuchi, Gary Remingto. Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction. Evidence-based mental health. vol 18. issue 4. 2016-01-22. PMID:26459470. |
improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine d2/3 receptor occupancy following risperidone and olanzapine dose reduction. |
2016-01-22 |
2023-08-13 |
Not clear |
| J Zhang, L Ye, W Wang, G Du, X Yu, X Zhu, Q Dong, X Cen, X Guan, F Fu, J Tia. A 12-week subchronic intramuscular toxicity study of risperidone-loaded microspheres in rats. Human & experimental toxicology. vol 34. issue 2. 2015-11-16. PMID:24812153. |
the main drug-related findings were contributed to the dopamine d2 receptor and α1-adrenoceptor antagonism of risperidone such as elevation of serum and pituitary prolactin levels and ptosis and changes in reproductive system (uterus, ovary, vagina, mammary gland, testis, seminal vesicle, epididymis, and prostate). |
2015-11-16 |
2023-08-13 |
rat |
| Linhui Liang, Yingcheng Wang, Jinxue Wei, Xiaochu Gu, Bo Xiang, Xiaohong Ma, Tao L. [Regulation of PI3K-Akt-GSK3β signaling pathway in U251 cells by risperidone]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics. vol 31. issue 6. 2015-03-24. PMID:25449069. |
to investigate the effect of risperidone, an antipsychotic drug, on the akt-gsk3β pathway and the role of pi3k in dopamine d2 receptor (drd2) expression and akt-gsk3β signal pathway. |
2015-03-24 |
2023-08-13 |
Not clear |
| Hiroyoshi Takeuchi, Takefumi Suzuki, Robert R Bies, Gary Remington, Koichiro Watanabe, Masaru Mimura, Hiroyuki Uchid. Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. The Journal of clinical psychiatry. vol 75. issue 11. 2015-02-09. PMID:25099201. |
dose reduction of risperidone and olanzapine and estimated dopamine d₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. |
2015-02-09 |
2023-08-13 |
Not clear |
| Keisuke Hazama, Atsuko Hayata-Takano, Kazuki Uetsuki, Atsushi Kasai, Naoki Encho, Norihito Shintani, Kazuki Nagayasu, Ryota Hashimoto, Dora Reglodi, Tsuyoshi Miyakawa, Takanobu Nakazawa, Akemichi Baba, Hitoshi Hashimot. Increased behavioral and neuronal responses to a hallucinogenic drug in PACAP heterozygous mutant mice. PloS one. vol 9. issue 2. 2015-01-27. PMID:24586556. |
mice with homozygous disruption of the pacap gene display profound behavioral and neurological abnormalities that are ameliorated with the atypical antipsychotic and dopamine d2 and serotonin (5-ht)2 antagonist risperidone and the 5-ht2 receptor antagonist ritanserin; however, the underlying mechanisms remain unknown. |
2015-01-27 |
2023-08-12 |
mouse |
| Celine M Laffont, Roberto Gomeni, Bo Zheng, Christian Heidbreder, Paul J Fudala, Azmi F Nasse. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. Clinical pharmacokinetics. vol 53. issue 6. 2015-01-19. PMID:24464285. |
population pharmacokinetics and prediction of dopamine d2 receptor occupancy after multiple doses of rbp-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. |
2015-01-19 |
2023-08-12 |
Not clear |
| Hiroshi Kimura, Nobuhisa Kanahara, Naoya Komatsu, Minoru Ishige, Katsumasa Muneoka, Masayuki Yoshimura, Hiroshi Yamanaka, Tomotaka Suzuki, Hideki Komatsu, Tsuyoshi Sasaki, Tasuku Hashimoto, Tadashi Hasegawa, Akihiro Shiina, Masatomo Ishikawa, Yoshimoto Sekine, Tetsuya Shiraishi, Hiroyuki Watanabe, Eiji Shimizu, Kenji Hashimoto, Masaomi Iy. A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophrenia research. vol 155. issue 1-3. 2014-12-17. PMID:24667073. |
a prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. |
2014-12-17 |
2023-08-12 |
Not clear |
| Danielle Gulick, David T Chau, Jibran Y Khokhar, Ree Dawson, Alan I Gree. Desipramine enhances the ability of risperidone to decrease alcohol intake in the Syrian golden hamster. Psychiatry research. vol 218. issue 3. 2014-12-10. PMID:24836200. |
another atypical antipsychotic, risperidone, which is a potent blocker of both the dopamine d2 receptor and norepinephrine α-2 receptor, does not decrease alcohol drinking. |
2014-12-10 |
2023-08-13 |
Not clear |
| b' Zofia Rog\\xc3\\xb3\\xc5\\xb. Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: preclinical and clinical efficacy. Pharmacological reports : PR. vol 65. issue 6. 2014-10-14. PMID:24553002.' |
combined treatment of rats with all studied atypical antipsychotics (olanzapine, risperidone, clozapine and quetiapine) and antidepressants (citalopram, fluoxetine and fluvoxamine) increased the extracellular level of dopamine in the prefrontal cortex compared to a respective drug given alone; in addition, a combination of olanzapine or quetiapine plus fluoxetine or fluvoxamine increased the levels of dopamine and noradrenaline. |
2014-10-14 |
2023-08-12 |
rat |
| Jennifer A Hadley, Rodolphe Nenert, Nina V Kraguljac, Mark S Bolding, David M White, Frank M Skidmore, Kristina M Visscher, Adrienne C Laht. Ventral tegmental area/midbrain functional connectivity and response to antipsychotic medication in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 39. issue 4. 2014-10-10. PMID:24165885. |
using resting-state functional mri, we examined the functional connectivity of the ventral tegmental area (vta), the origin of the mesocorticolimbic dopamine projections, in 21 healthy controls and 21 unmedicated patients with schizophrenia at baseline (pre-treatment) and after 1 week of treatment with the antipsychotic drug risperidone (1-week post-treatment). |
2014-10-10 |
2023-08-12 |
Not clear |